Literature DB >> 33005656

Readmissions after Pancreatic Surgery in Patients with Pancreatic Cancer: Does Hospital Variation Exist for Quality Measurement?

Ching-Yu Wang1, Joshua Brown1.   

Abstract

BACKGROUND: The appropriateness of using readmission rate after pancreatic surgery among pancreatic cancer patients as a quality metric to evaluate hospital performance has been widely discussed in the literature.
OBJECTIVES: The present study reported readmission rate using Nationwide Readmissions Database (NRD), examined the reasons and risk factors for readmissions, and evaluated the appropriateness of using it as a quality metric.
METHOD: We analyzed 3,619 patient discharge records in 2014. The outcome of interest was all-cause 30-day readmission. Reasons for readmission were grouped into clinical associated categories. Hierarchical regression model was used for examining the relationship between risk factors and readmission.
RESULTS: The 30-day readmission rate was 20.95%. The most common reason for readmission was surgery-related complication. In descriptive analyses, age, certain comorbidities, number of chronic conditions, mortality risk, severity of illness, living at large metropolitan area, resident of the state where patients received initial care, postoperative complication, length of stay, discharge location, and receiving care at the hospitals in large metropolitan area were predictive of readmission. In multivariable analysis, age, depression, peripheral vascular disorder, mortality risk, and discharge location were independently associated with readmission. The intraclass correlation coefficient was 0.41 for hierarchical regression model.
CONCLUSIONS: Readmission after pancreatic surgery remains an important issue. Our study found the majority of variation in readmissions is accounted for by patient factors whereas there was little between hospital variation. This finding does not support the use of readmission rate after pancreatic surgery as a quality metric.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Administrative data; Pancreatic surgery; Quality of care; Readmission rate

Year:  2019        PMID: 33005656      PMCID: PMC7506284          DOI: 10.1159/000502894

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  17 in total

1.  Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas.

Authors:  G Benassai; M Mastrorilli; G Quarto; A Cappiello; U Giani; G Mosella
Journal:  Chir Ital       Date:  2000 May-Jun

2.  Readmission After Pancreaticoduodenectomy: The Influence of the Volume Effect Beyond Mortality.

Authors:  Jeffrey M Sutton; Gregory C Wilson; Koffi Wima; Richard S Hoehn; R Cutler Quillin; Dennis J Hanseman; Ian M Paquette; Jeffrey J Sussman; Syed A Ahmad; Shimul A Shah; Daniel E Abbott
Journal:  Ann Surg Oncol       Date:  2015-04-04       Impact factor: 5.344

3.  Hospital readmission after a pancreaticoduodenectomy: an emerging quality metric?

Authors:  Zachary J Kastenberg; John M Morton; Brendan C Visser; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2012-09-24       Impact factor: 3.647

4.  Readmission after colectomy for cancer predicts one-year mortality.

Authors:  David Yu Greenblatt; Sharon M Weber; Erin S O'Connor; Noelle K LoConte; Jinn-Ing Liou; Maureen A Smith
Journal:  Ann Surg       Date:  2010-04       Impact factor: 12.969

5.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.

Authors:  C J Yeo; J L Cameron; T A Sohn; K D Lillemoe; H A Pitt; M A Talamini; R H Hruban; S E Ord; P K Sauter; J Coleman; M L Zahurak; L B Grochow; R A Abrams
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

6.  Readmission after pancreatic resection is not an appropriate measure of quality.

Authors:  Irmina Gawlas; Monica Sethi; Megan Winner; Irene Epelboym; James L Lee; Beth A Schrope; John A Chabot; John D Allendorf
Journal:  Ann Surg Oncol       Date:  2012-12-08       Impact factor: 5.344

7.  Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study.

Authors:  K E Bakkevold; B Arnesjø; O Dahl; B Kambestad
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients.

Authors:  Syed A Ahmad; Michael J Edwards; Jeffrey M Sutton; Sanjeet S Grewal; Dennis J Hanseman; Shishir K Maithel; Sameer H Patel; David J Bentram; Sharon M Weber; Clifford S Cho; Emily R Winslow; Charles R Scoggins; Robert C Martin; Hong Jin Kim; Justin J Baker; Nipun B Merchant; Alexander A Parikh; David A Kooby
Journal:  Ann Surg       Date:  2012-09       Impact factor: 12.969

9.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

10.  Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal.

Authors:  Irina Yermilov; David Bentrem; Evan Sekeris; Sushma Jain; Melinda A Maggard; Clifford Y Ko; James S Tomlinson
Journal:  Ann Surg Oncol       Date:  2008-11-11       Impact factor: 5.344

View more
  1 in total

1.  E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1.

Authors:  Xueqiang Deng; Xiaowei Fu; Hong Teng; Lu Fang; Bo Liang; Rengui Zeng; Lian Chen; Yeqing Zou
Journal:  J Transl Med       Date:  2021-08-05       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.